Revolution Medicines Reports Updated Clinical Data for RMC-6236 in PDAC Patients

Details

reported updated clinical safety, tolerability, and activity data for RMC-6236, its RAS(ON) multi-selective inhibitor, from its Phase 1 clinical trial in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). The data, as of a July 23, 2024 cutoff, indicated that the most common treatment-related adverse events were rash and gastrointestinal-related toxicities. One Grade 4 adverse event was observed, but no Grade 5 events were reported. Preliminary progression-free survival (PFS) data showed median PFS of 8.5 months for patients with KRAS G12X mutations and 7.6 months for patients with G12, G13, or Q61 mutations in the second-line treatment setting. In the third-line or later setting, median PFS was 4.4 months for both KRAS G12X and G12, G13, or Q61 mutations. Overall survival (OS) data showed a median OS of 14.5 months for patients with KRAS G12X mutations and 14.5 months for those with G12, G13, or Q61 mutations in the second-line setting. The best overall response rate was 29% in the second-line setting and 22% in the third-line or later setting.

Items reported

About Revolution Medicines Inc.

Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.